A phase I/II study of LOAd703, a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus, combined with nab-paclitaxel and gemcitabine in advanced pancreatic cancer.

Benjamin Musher(Baylor College of Medicine), Angelica Sara Ingrid Loskog(Uppsala University), Eric K. Rowinsky, Salmaan Jawaid(Baylor College of Medicine), Brandon G. Smaglo(The University of Texas MD Anderson Cancer Center), Gustav Ullenhag(Uppsala University), Amanda Brisco(University of South Florida), Linda C. Sandin, Malcolm K. Brenner, Wasif M. Abidi(Baylor College of Medicine), Mohamed O. Othman(Baylor College of Medicine), Susan G. Hilsenbeck(Baylor College of Medicine), James Jing(Baylor College of Medicine), Justyna Leja-Jarblad, Kalpesh Patel(Baylor College of Medicine), Bambi Grilley(Baylor College of Medicine), Emma Eriksson(Uppsala University), Jessica Wenthe(Uppsala University)
Journal of Clinical Oncology
June 1, 2022
Cited by 19


Related Papers